Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database
J Clin Psychiatry. 2023 Sep 27;84(6):23br14923. doi: 10.4088/JCP.23br14923.NO ABSTRACTPMID:37756127 | DOI:10.4088/JCP.23br14923 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Francesco Salvo Jean-Arthur Micoulaud-Franchi Laura Palagini Pierre A Geoffroy Source Type: research
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
Conclusions: This post hoc analysis suggests that PP provides significant benefit in reducing TF or relapse compared with OAPs regardless of duration of illness and highlights the potential benefit of implementing PP earlier in the course of schizophrenia.Trial Registration: ClinicalTrials.gov identifiers NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM).PMID:37756123 | DOI:10.4088/JCP.23m14788 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Oliver J Lopena Larry D Alphs Martha Sajatovic Ibrahim Turkoz Liping Sun Karen L Johnston Jennifer K Sliwa Dean M Najarian H Lynn Starr Source Type: research
Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database
J Clin Psychiatry. 2023 Sep 27;84(6):23br14923. doi: 10.4088/JCP.23br14923.NO ABSTRACTPMID:37756127 | DOI:10.4088/JCP.23br14923 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Francesco Salvo Jean-Arthur Micoulaud-Franchi Laura Palagini Pierre A Geoffroy Source Type: research
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
Conclusions: This post hoc analysis suggests that PP provides significant benefit in reducing TF or relapse compared with OAPs regardless of duration of illness and highlights the potential benefit of implementing PP earlier in the course of schizophrenia.Trial Registration: ClinicalTrials.gov identifiers NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM).PMID:37756123 | DOI:10.4088/JCP.23m14788 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Oliver J Lopena Larry D Alphs Martha Sajatovic Ibrahim Turkoz Liping Sun Karen L Johnston Jennifer K Sliwa Dean M Najarian H Lynn Starr Source Type: research
Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database
J Clin Psychiatry. 2023 Sep 27;84(6):23br14923. doi: 10.4088/JCP.23br14923.NO ABSTRACTPMID:37756127 | DOI:10.4088/JCP.23br14923 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Francesco Salvo Jean-Arthur Micoulaud-Franchi Laura Palagini Pierre A Geoffroy Source Type: research
